{"filings":[{"id":2190996,"accession_number":"0001376339-26-000082","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K/A","filed_at":"2026-08-11T20:44:09+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"MiMedx corrects termination fees in Sanara merger; Sanara fee $9.66M, MiMedx fee $22.54M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Termination fee payable by Sanara to MiMedx corrected to $9,660,336 (previously misstated as $22,540,785).","Termination fee payable by MiMedx to Sanara corrected to $22,540,785 (previously misstated as $9,660,336).","Merger consideration: $33.00 cash + 0.4735 MiMedx shares per Sanara share (stock portion valued at ~$2.00).","MiMedx secured $300M first-lien senior secured term loan from Hayfin Capital Management for the merger.","Voting agreement with Sanara stockholders holding ~38.9% of voting power to support the deal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1940638,"accession_number":"0001376339-26-000074","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2026-07-29T20:08:19+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MiMedx Q2 net sales $64M (-35% YoY); to acquire Sanara MedTech for ~$350M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Net sales $64M vs $99M YoY; net loss $15M vs net income $10M YoY.","Surgical product sales +15% YoY; Wound sales -61% YoY due to Medicare changes.","Acquiring Sanara MedTech (SMTI) for $35/share ($33 cash + 0.4735 MDXG shares); ~$350M enterprise value.","Consideration represents 46% premium to Sanara's 30-day VWAP; expected close by year-end.","Financing via cash on hand and $300M term loan from Hayfin; FY2026 net sales guidance reiterated at $260-290M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1940477,"accession_number":"0001376339-26-000070","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2026-07-29T20:03:54+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"MiMedx to acquire Sanara MedTech for $35/share in cash and stock, ~$350M enterprise value","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["MiMedx to acquire Sanara MedTech for $35 per share ($33 cash + 0.4735 MDXG shares), total enterprise value ~$350M.","Transaction expected to be immediately accretive to revenue growth, gross margin, and adjusted EBITDA margin; over $20M in run-rate cost synergies.","MiMedx secured $300M debt commitment from Hayfin Capital Management to finance cash consideration and refinance existing debt.","Sanara stockholders holding ~38.9% of voting power have agreed to vote in favor via voting agreement.","Closing expected late 2026/early 2027, subject to Sanara stockholder approval, HSR clearance, and other conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1083996,"accession_number":"0001376339-26-000052","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2026-06-16T20:12:31+00:00","items":["5.03","5.07"],"status":"ready","headline":"MiMedx amends bylaws to allow CEO to serve on up to three public boards; shareholders re-elect seven directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Bylaw amendment increases CEO's permissible public-company board seats from two to three.","Shareholders re-elected Joseph H. Capper, James L. Bierman, William A. Hawkins, III, K. Todd Newton, Tiffany Olson, Dorothy Puhy, and Martin P. Sutter.","Advisory vote on executive compensation approved with 95.2M for, 4.4M against, 2.2M abstain.","Ratification of Deloitte & Touche as independent auditor for FY2026 approved with 123.7M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92505,"accession_number":"0001376339-26-000032","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MiMedx Q1 net sales $59M (-33% YoY), loss $11M; cuts FY guidance to $260-290M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net sales $59M, down 33% YoY from $88M; net loss $11M vs net income $7M a year ago.","Surgical product sales up 13% YoY; Wound sales down 60% due to Medicare payment cap per cm².","Gross margin fell to 71% from 81% on pricing pressure and unfavorable product mix.","FY2026 net sales guidance lowered to $260-290M; Adjusted EBITDA expected approximately breakeven.","Company plans $40M annualized cost savings; CEO targets return to profitability in H2 and double-digit growth in 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":58991000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92504,"accession_number":"0001376339-26-000021","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"MiMedx Announces Restructuring and $40M Annual Cost Reduction Initiative","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Eliminated Chief Operating Officer position held by Ricci Whitlow; her departure effective immediately.","CEO Joe Capper's base salary reduced by 20%; other named executive officers receive 10% salary reductions through Dec 31, 2026.","Company expects annualized savings of approximately $40 million; expects one-time restructuring charge of ~$4 million in Q2 2026.","Cost reduction due to slower-than-expected recovery in Wound Care business following January 1 Medicare reimbursement cut.","Surgical business continues to grow and warrants additional investments; restructuring to streamline operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103383,"accession_number":"0001376339-26-000012","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MiMedx posts record Q4 sales $118M (+27% YoY); 2026 guidance $340-360M; $100M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $118M, +27% YoY; full-year $419M, +20% YoY.","Q4 GAAP net income $15M ($0.10 EPS); Adjusted EBITDA $29M (25% margin).","2026 net sales guidance $340-360M, down from 2025 actual; Adj EBITDA margin mid-to-high teens.","Board authorizes $100M share repurchase program over two years.","Cash & equivalents $166M; net cash $148M; SG&A up 18% to $266M on higher commissions."],"consensus_eps_estimate":null,"consensus_eps_actual":0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":418630000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103382,"accession_number":"0001376339-26-000003","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MiMedx updates investor presentation on January 12, 2026; no specific data available","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["MiMedx updated its investor slide presentation on January 12, 2026.","Only a disclaimer header is visible in the furnished exhibit; presentation content not provided.","No financial results, guidance, or material changes are disclosed in the filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119624,"accession_number":"0001376339-25-000104","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MiMedx Q3 record revenue $114M (+35% YoY); raises FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net sales $114M, up 35% YoY; GAAP net income $17M, diluted EPS $0.11.","Adjusted EBITDA $35M, 31% of net sales; Wound product sales grew 40%, Surgical 26%.","Cash and equivalents $142M at Sept 30, up from $104M at Dec 31, 2024.","2025 outlook raised: net sales growth mid-to-high teens, adjusted EBITDA margin at least mid-20%.","CEO cites record revenue, cash flow; awaiting final 2026 CMS reimbursement rules."],"consensus_eps_estimate":null,"consensus_eps_actual":0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":300535000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136197,"accession_number":"0001376339-25-000093","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MiMedx updates investor deck for Cantor conference; no specific new metrics revealed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company to participate in Cantor Global Healthcare Conference on September 3, 2025.","Updated investor slide presentation furnished as Exhibit 99.1.","Presentation includes forward-looking statements and risk factors; no financial guidance changes disclosed.","Exhibit text provided is incomplete; no specific operational or financial figures available."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136196,"accession_number":"0001376339-25-000087","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MiMedX Q2 net sales $99M record, up 13% YoY; raises 2025 growth to low double-digits","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $99M (record), +13% YoY; GAAP net income $10M ($0.06 EPS); prior year included $9.3M settlement benefit.","Adjusted EBITDA $24M (25% margin); cash $119M, up $15M from Dec 2024.","Wound sales +12%, Surgical +15% YoY; driven by new products CELERA, EMERGE, HELIOGEN.","Raises 2025 net sales growth outlook to low double-digits; reaffirms adjusted EBITDA margin above 20%.","CEO supports CMS proposal to overhaul skin substitute reimbursement; engaging in comment period."],"consensus_eps_estimate":null,"consensus_eps_actual":0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":186810000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153274,"accession_number":"0001376339-25-000059","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MiMedx shareholders re-elect nine directors and approve executive compensation at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders re-elected all nine director nominees including M. Kathleen Behrens, Joseph H. Capper, and William A. Hawkins.","Advisory resolution on executive compensation approved with 94.8 million votes for and 6.9 million against.","Ratification of Deloitte & Touche as independent auditor for fiscal 2025 approved with 123.7 million votes for.","Amendment of the 2016 Equity and Cash Incentive Plan approved with 91.4 million votes for.","Shareholders voted for an annual frequency of say-on-pay votes (97.5 million for one year)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153273,"accession_number":"0001376339-25-000053","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MiMedx updates investor presentation for BofA healthcare conference on May 13, 2025","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company participated in BofA Securities 2025 Healthcare Conference on May 13, 2025.","Filed updated investor slide deck as Exhibit 99.1; full presentation content not provided in this filing extract.","No specific financial or strategic updates are identifiable from the limited exhibit text available.","Routine FD disclosure; no forward-looking guidance or material changes were disclosed in the 8-K body.","Investors should review the complete presentation for any new information."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153272,"accession_number":"0001376339-25-000044","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MiMedx Q1 net sales $88M (+4% YoY); GAAP EPS $0.05; reaffirms high single-digit growth outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $88M (+4% YoY); GAAP net income $7M ($0.05 EPS); Adj. EBITDA $17M (20% margin).","Gross margin fell to 81% from 85% on product mix; Surgical products grew 16%, Wound fell 2%.","Cash $106M; net debt $0; 2025 outlook: high single-digit sales growth and >20% Adj. EBITDA margin.","CEO calls LCD delay disappointing; added CELERA product as contingency for affected settings.","SG&A rose to $60M from $55M on higher commissions, salaries, and legal/regulatory costs."],"consensus_eps_estimate":null,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":88205000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172043,"accession_number":"0001376339-25-000013","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MiMedx updates investor presentation; specific content not available in filing excerpt","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Investor presentation dated February 27, 2025, furnished under Regulation FD.","No financial targets, guidance changes, or operational metrics disclosed in the provided text.","Full slide deck is not included in the excerpt; investors should seek the complete presentation for details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172042,"accession_number":"0001376339-25-000011","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MiMedx Q4 net sales $93M (+7% YoY), Adjusted EBITDA margin 21%, guides high-single-digit growth for 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 net sales $93M (+7% YoY); full year $349M (+9% YoY). Adjusted EBITDA margin 21% for Q4.","GAAP net income Q4 $7M ($0.05 EPS); full year $42M. Cash $104M at Dec 31, net cash $86M.","2025 outlook: net sales growth at least high single-digits, Adjusted EBITDA margin above 20%.","SG&A increased to $61M in Q4 from $54M a year ago; CEO cites Medicare disruption but remains confident."],"consensus_eps_estimate":null,"consensus_eps_actual":0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":348879000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172041,"accession_number":"0001193125-25-005766","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MiMedx updates investor presentation; no material changes disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Investor presentation updated on January 14, 2025.","No specific financial, operational, or strategic updates provided in the filing.","Presentation content not fully available; confidence in material impact low."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189036,"accession_number":"0001193125-24-279618","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"MiMedx extends HQ lease through July 2029 and adopts director/officer indemnification agreements","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease with CPVF II West Oak LLC extended from July 31, 2026 to July 31, 2029; two optional two-year extensions added.","Amendment provides tenant improvement funds from landlord and modifies rent terms; headquarters remains in Marietta, GA.","Board approved form of Indemnification Agreement for all directors and executive officers to fullest extent under Florida law.","Indemnification agreements cover expenses, advancements, and procedures for claims arising from service to company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189035,"accession_number":"0001193125-24-260490","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MiMedx Group presents at two investor conferences; slide deck furnished","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Senior management to present at Stifel 2024 Healthcare Conference on Nov 18 and Craig-Hallum Capital Group 15th Annual Alpha Select Conference on Nov 19.","Slide presentation furnished as Exhibit 99.1; no specific financial or operational updates are included in the 8-K filing text.","The exhibit content is not fully provided in this excerpt, so no material new information from the slides can be summarized.","This is a routine Regulation FD disclosure with no new earnings, guidance, or corporate actions announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189034,"accession_number":"0001193125-24-247640","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MiMedx Q3 net sales $84M (+3% YoY); raises FY2024 growth outlook to high single-digits","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $8.1M ($0.05 EPS); Adjusted EBITDA $18.2M (21.6% margin), up from $17.6M a year ago.","Cash and cash equivalents $89M; net cash position $70M, up $20M sequentially.","2024 net sales growth guidance raised to high single-digits (from mid-to-high single-digits); Adjusted EBITDA margin expected above 20%.","Q3 gross margin 81.8% vs 81.9% prior year; growth driven by AMNIOEFFECT, EPIEFFECT and HELIOGEN products."],"consensus_eps_estimate":null,"consensus_eps_actual":0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":255972000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205515,"accession_number":"0001193125-24-189932","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MiMedx Q2 revenue $87M (+7% YoY), GAAP EPS $0.12, Adjusted EBITDA margin 23%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $87M, up 7% YoY; GAAP net income $18M, EPS $0.12.","Adjusted EBITDA $20M, margin 23% vs 17.4% in Q2 2023.","CEO reports competitive pressure from high-priced skin substitutes causing employee and customer attrition.","Launched HELIOGEN (first xenograft) and commenced RCT for EPIEFFECT.","Cash $69M; 2024 net sales growth guided to mid-to-high single digits."],"consensus_eps_estimate":null,"consensus_eps_actual":0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":171915000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222444,"accession_number":"0001376339-24-000055","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MiMedx shareholders re-elect all nine directors, approve say-on-pay at AGM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["80.74% of shares represented; all nine director nominees re-elected with substantial votes for (over 88M each).","Advisory say-on-pay resolution passed with 68.7M for, 24.0M against, 1.1M abstentions.","Ratification of Deloitte & Touche as auditor for FY2024 approved with 116.7M for, 2.3M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222443,"accession_number":"0001193125-24-125073","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MiMedx Q1 net sales $85M (+18% YoY); GAAP net income $9M; Adj. EBITDA $19M (22% margin)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $85M, up 18% YoY; gross margin improved to 84.7% from 82.7%.","GAAP net income $9M vs loss of $5M in prior year; Adjusted EBITDA $19M (22% margin) vs $5.5M (7.7%).","Cash $48M at March 31, down from $82M at Dec 31, due to repaying $30M revolver and $5M TELA Bio payment.","Signed distribution agreement with Regenity Biosciences for 510(k)-cleared collagen xenograft; launch expected later in 2024.","Appointed two new independent directors; launched MIMEDX Connect online ordering platform."],"consensus_eps_estimate":null,"consensus_eps_actual":0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":84709000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241968,"accession_number":"0001376339-24-000026","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2024-03-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA rules AXIOFILL does not qualify as HCT/P; MiMedx to sue, reiterates 2024 guidance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA determined AXIOFILL does not meet HCT/P criteria under Section 361, treating it as a 351 biologic product.","MiMedx files suit in U.S. District Court for Northern District of Georgia to challenge FDA's decision.","Company plans to continue marketing AXIOFILL while legal proceedings are ongoing.","Reiterates 2024 guidance: low double-digit net sales growth, adjusted EBITDA margin above 20%.","Acquired exclusive rights to bovine-derived collagen particulate from Regenity Biosciences for new product later in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241967,"accession_number":"0001376339-24-000011","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"MiMedx expands board to 11, appoints Olson and Puhy as independent directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Tiffany Olson and Dorothy Puhy as independent directors, effective March 1, 2024.","Board size increased from nine to eleven members.","Olson and Puhy bring healthcare and executive leadership experience to the board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241966,"accession_number":"0001193125-24-050739","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MiMedx Q4 net sales $87M (+17% YoY); FY $321M (+20%); guides 2024 low double-digit growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales Q4 $87M, FY $321M, up 17% and 20% YoY respectively.","GAAP net income Q4 $53M (incl. $40M one-time tax benefit), FY $58M.","Adjusted EBITDA Q4 $21M, margin 24%.","2024 guidance: low double-digit net sales growth, adjusted EBITDA margin >20%.","Launched EPIEFFECT wound care product; completed debt refinancing Jan 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":321477000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241965,"accession_number":"0001193125-24-011707","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2024-01-22T23:59:59+00:00","items":["1.01","1.02","2.03","7.01","9.01"],"status":"ready","headline":"MiMedx closes $95M senior secured credit facilities; reduces interest expense","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New facilities: $75M revolver + $20M term loan, due Jan 2029.","Drew $50M at closing; proceeds repaid existing Hayfin credit facility (maturity June 2025).","Interest rates: SOFR + 2.25%-3.50% or base rate +1.25%-2.50%.","CFO states refinancing improves capital structure, provides borrowing capacity for growth.","Arranged by Citizens Bank and Bank of America; Hayfin agreement terminated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259385,"accession_number":"0001193125-23-305186","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2023-12-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MiMedx converts 95,000 Series B Preferred shares into 30M common shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["95,000 shares of Series B Convertible Preferred Stock converted into approx. 30M shares of common stock on Dec 22, 2023.","Conversion ends all dividend accrual obligations tied to the Preferred Stock.","Triggered by higher common stock price and third anniversary of July 2020 financing.","CEO states conversion simplifies balance sheet and positions for future growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259384,"accession_number":"0001193125-23-275400","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MiMedx management to present at three investor conferences in Nov-Dec 2023","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Craig-Hallum Alpha Select Conference on Nov 16, 2023 in New York.","Mizuho Medical Device & Healthcare Services Summit on Dec 6, 2023 in New York.","Stifel MedTech West Coast Bus Tour on Dec 14, 2023 in Palo Alto, CA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259383,"accession_number":"0001193125-23-266161","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2023-10-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MiMedx Q3 net sales up 20.7% to $81.7M, GAAP net income $8.5M, raises FY outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net sales $81.7M (+20.7% YoY); GAAP net income $8.5M vs loss $8.4M prior year.","Adjusted EBITDA $17.6M (21.6% margin) vs $2.4M; cash from ops $12.8M.","Raised FY2023 net sales growth outlook to high teens; expects H2 Adj. EBITDA margin >20%.","Repurchased $9.5M of Series B Preferred Stock from Hayfin; one-year lock-up.","Cash $81.2M, up from $66.0M at Dec 31, 2022; long-term debt $49.0M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":234645000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276654,"accession_number":"0001376339-23-000066","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2023-09-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"MiMedx combines CFO and CAO roles; CAO William Phelan retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Effective Sept 1, 2023, CFO Doug Rice assumed the combined CFO and CAO role.","Former CAO William Phelan retired as part of the role consolidation.","No dispute or disagreement; retirement is not due to any conflict.","Change reflects normal organizational streamlining at MiMedx."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276653,"accession_number":"0001193125-23-228137","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2023-09-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MiMedx to participate in three investor conferences in September 2023","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Presenting at H.C. Wainwright 25th Annual Global Investment Conference on Sept 12 at 12:30 PM ET.","Presenting at Northland Capital Markets Institutional Investor Conference on Sept 19.","Presenting at Cantor Fitzgerald Global Healthcare Conference 2023 on Sept 27 at 10:55 AM ET.","Live webcasts will be available on the company's website following the events."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276652,"accession_number":"0001193125-23-200535","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2023-08-01T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MiMedx Q2 net sales $81.3M (+21.5% YoY); raises FY2023 growth guidance to mid-to-high teens","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $81.3M (+21.5% YoY); net income $1.2M; Adj. EBITDA $14.1M (17.4% of sales).","Raises full-year 2023 net sales growth guidance to mid-to-high teens.","Appoints Doug Rice as CFO, rounding out executive team.","Reports favorable appellate ruling affirming dismissal of securities class action.","Announced strategic realignment focusing on Wound & Surgical businesses to improve profitability."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":152933000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276651,"accession_number":"0001376339-23-000055","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2023-07-05T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"MiMedx appoints Doug Rice as CFO; Peter Carlson resigns effective July 5, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Doug Rice, former CFO of Orthofix Medical, named CFO effective July 5, 2023.","Peter Carlson resigned as CFO effective same date.","Rice receives base salary of $540,000 and target cash bonus of 60% of base.","Inducement grants: 162,000 PSUs (3-yr performance), 97,200 RSUs (3-yr vest), 94,000 options (4-yr vest).","Rice brings experience from Orthofix, Vision Source, McAfee; is a CPA and MBA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294424,"accession_number":"0001376339-23-000046","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"MiMedx suspends KOA program, focuses on wound care, raises 2023 sales guidance to mid-teens growth","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Suspending knee osteoarthritis program and disbanding Regenerative Medicine unit; President Dr. Stein departing.","Expects ~$25M annualized Adjusted EBITDA savings; one-time wind-down costs of ~$5M.","Raises 2023 net sales growth outlook from low-double digits to mid-teens.","Focus on Wound & Surgical business to drive profitability and cash flow.","Conference call at 5:30pm ET today to discuss strategic realignment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294423,"accession_number":"0001376339-23-000033","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2023-06-14T23:59:59+00:00","items":["5.02","5.07","5.03","9.01"],"status":"ready","headline":"Shareholders approve increase in authorized shares and equity plan amendment at 2023 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved raising authorized common shares from 187.5M to 250M (~81% in favor); amendment filed and effective June 14, 2023.","Approved amendment and restatement of 2016 Equity and Cash Incentive Plan (~77% in favor).","Re-elected directors Bierman, Gardner, Giuliani, Laurencin; say-on-pay passed ~89%; Deloitte ratified as auditor ~97%.","All five proposals at June 13, 2023 annual meeting were approved by requisite vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294422,"accession_number":"0001193125-23-132450","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2023-05-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MiMedx Q1 net sales $71.7M (+21.7% YoY); net loss narrows to $5.0M; Adj. EBITDA $5.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $71.7M in Q1 2023, up 21.7% from $58.9M in Q1 2022.","Net loss improved to $5.0M from $10.5M in prior year; Adjusted EBITDA of $5.5M.","CEO attributed growth to robust demand for new surgical products and accelerated growth in private physician offices.","Gross margin improved sequentially; operating expenses grew slower than sales.","Company also announced an upcoming Chief Financial Officer transition."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":71676000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315028,"accession_number":"0001193125-23-079148","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2023-03-24T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"MiMedx CFO Peter Carlson resigns; search for successor initiated","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Peter M. Carlson leaves to pursue other opportunities; effective date to be mutually agreed.","Company has initiated a search for next CFO; Carlson will assist during transition.","CEO Capper cites Carlson's role in raising debt/equity, de-listing turnaround, and internal controls."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315027,"accession_number":"0001193125-23-053829","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MiMedx Q4 net sales $74.4M, up 10.3% YoY; adjusted EBITDA $7.3M; new CEO Capper appointed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $74.4M (+10.3% YoY); full year $267.8M (+3.6%). Highest quarterly since Q4 2019.","Q4 net loss $0.4M vs net income $2.2M in prior year; FY net loss $30.2M vs $10.3M.","Adjusted EBITDA Q4 $7.3M (improved from $3.6M); FY adjusted EBITDA $3.9M (from $18.7M).","Appointed Joseph H. Capper as CEO and Director; Ricci S. Whitlow as COO.","Commenced first registrational trial of mDHACM for knee osteoarthritis; launched EPIFIX in Japan via GUNZE."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":267841000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315026,"accession_number":"0001193125-23-046821","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"MiMedx amends bylaws to address universal proxy rules and make technical changes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved amended and restated Bylaws effective February 16, 2023.","Amendments clarify compliance with SEC Rule 14a-19 universal proxy rules for director nominations.","Incorporate changes from Amendment No. 1 adopted May 27, 2021.","Include technical, modernizing, and clarifying updates to the Bylaws."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315025,"accession_number":"0001193125-23-018383","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2023-01-30T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"MiMedx appoints ex-BioTelemetry CEO Joseph H. Capper as CEO, effective Jan 27","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Joseph H. Capper as CEO and director, effective Jan 27, 2023; Todd Newton steps down as interim CEO but remains on board.","Capper receives $750k salary, 100% target bonus, 3.3M PSUs (4-yr vest), and option for 3.6M shares at $3.70 strike.","Capper previously led BioTelemetry, acquired by Philips for $2.8B; has ~30 years MedTech/Life Sciences experience.","Inducement PSUs and option granted outside equity plan under Nasdaq Rule 5635(c)(4)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315024,"accession_number":"0001193125-23-004193","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MiMedx reaffirms Q4/FY2022 sales; warns of Medicare reimbursement risk for skin substitutes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q4 2022 net sales expected $73M-$76M; FY2022 $266M-$269M, unchanged from Nov 2022 guidance.","About 28% of 2022 sales from private physician office; ~75% of that reimbursed by CMS, over 90% is EPIFIX.","Received FDA TRG letter confirming EPIFIX as Section 361 product in Dec 2022; seeking confirmation for EPICORD.","Restructuring headcount reductions expected to cut annualized costs by ~$5M; sales force realigned for productivity.","Entered distribution partnership with Gunze Medical for EPIFIX in Japan; appointed Ricci Whitlow as COO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315023,"accession_number":"0001193125-23-000889","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2023-01-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"MiMedx appoints Ricci S. Whitlow as COO effective January 3, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Whitlow most recently President, Clinical Supply Services at Catalent; 30+ years MedTech experience.","Compensation: base salary $540k, target bonus 50% of base, sign-on $50k, RSU grant of 300% of base salary.","Will lead manufacturing, supply chain, procurement, quality, and regulatory functions.","Severance benefits: 1.25x base+bonus for no-cause termination, 1.5x upon change in control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333376,"accession_number":"0001193125-22-307354","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2022-12-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"MiMedx President Rohit Kashyap resigns effective Jan 3, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Rohit Kashyap, President of Wound Care and Surgical, tendered resignation effective January 3, 2023.","Resignation not due to any dispute or disagreement with MiMedx or its Board.","No replacement named or immediate succession plan disclosed in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333375,"accession_number":"0001193125-22-300537","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2022-12-08T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"MiMedx licenses Turn's PermaFusion platform for $1M upfront, up to $9.55M in milestones for FleX AM product rights","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MiMedx obtains exclusive worldwide license to Turn's PermaFusion antimicrobial platform for wound, burn, and surgical fields.","Upfront cash payment of $1 million; potential milestone payments up to $9.55 million upon FDA 510(k) clearance of FleX AM product.","MiMedx acquires commercial rights to FleX AM, a particulate bovine collagen powder with antimicrobial properties, expected FDA clearance in 2023.","Turn will receive royalties on sales of products developed using the licensed technology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333374,"accession_number":"0001193125-22-294890","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2022-11-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MiMedx management to present at Piper Sandler Healthcare Conference; no financial updates disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Interim CEO K. Todd Newton, CFO Peter M. Carlson, and IR head Matthew Notarianni attending.","Conference on November 30, 2022; presentation furnished as Exhibit 99.1.","Filing provides no new financial or operational specifics beyond the presentation title."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333373,"accession_number":"0001193125-22-287241","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2022-11-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MiMedx attends Canaccord conference with standard investor presentation","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Executives attending Canaccord MedTech Forum on Nov 17, 2022; slide deck furnished as Exhibit 99.1.","Slide deck titled 'A Pioneer & Leader in Placental Biologics'; no new financial data disclosed.","Filing under Regulation FD; information not deemed filed or incorporated by reference.","No material operational or financial updates provided in the 8-K or exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333372,"accession_number":"0001193125-22-275856","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2022-11-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MiMedx Q3 net sales $67.7M (+7.3% YoY); net loss widens to $8.4M; launches two surgical products","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $67.7M, up 7.3% YoY; net loss $8.4M vs $2.3M loss prior year; adjusted EBITDA loss $0.7M vs gain $7.0M.","Launched AXIOFILL and AMNIOEFFECT for surgical recovery; obtained Japan reimbursement for EPIFIX.","Appointed Todd Newton interim CEO; new segment reporting for Wound & Surgical and Regenerative Medicine.","Advanced KOA registrational study with FDA, including Type B RMAT meeting and CMC filings."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":193466000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350869,"accession_number":"0001193125-22-246472","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2022-09-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"MiMedx appoints Todd Newton as Interim CEO; former CEO Wright receives $3.1M severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["K. Todd Newton named interim CEO effective Sept 14, 2022; monthly salary of $54,166.67.","Newton receives 200,000 RSUs vesting on one-year anniversary or earlier upon certain events.","Former CEO Timothy Wright receives $3,105,000 severance (24 months salary + 2x bonus).","Wright will provide consulting services at $500/hour up to 8 hours per week post-termination.","Newton to continue as Board member after interim CEO role; eligibility for 2023 equity incentive."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350868,"accession_number":"0001376339-22-000112","cik":1376339,"company_name":"MIMEDX GROUP, INC.","ticker":"MDXG","form_type":"8-K","filed_at":"2022-09-06T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"MiMedx appoints Todd Newton interim CEO; 2022 revenue growth outlook at low end of prior range","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Timothy R. Wright terminated as CEO effective immediately; K. Todd Newton appointed interim CEO.","Board formed Search Committee to find permanent CEO; includes Behrens, Bierman, Hawkins.","Board reduced to eight members; Newton no longer independent; Laurencin appointed to Audit Committee.","2022 full-year AWC product net sales expected at low end of 11-14% growth range (2021: $240M).","Q3 2022 AWC product net sales expected mid-single-digit growth vs Q3 2021 ($62.3M); total net sales expected to grow."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":541417748.3864267,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-09-06T23:59:59+00:00|350868"}